OPKO Health Q1 revenue falls after asset sales

OPKO Health

28/04/2026 21:22

Corrects Q1 Revenue from Services in Key Details table to $72.2 mln

Overview

US biopharma and diagnostics firm's Q1 revenue fell yr/yr after asset sales in 2025

Net loss and operating loss narrowed from prior year

Company repurchased $4.8 mln of its stock in Q1; $108 mln remains authorized

Outlook

OPKO Health sees Q2 total revenue between $127 mln and $132 mln

Company gives full-year 2026 revenue guidance of $530 mln to $560 mln

OPKO expects to file IND application for oral long-acting PTH tablet in late 2026

Result Drivers

ASSET SALES - Co said lower Q1 revenue was mainly due to sale of certain BioReference assets in 2025

DIAGNOSTICS REVENUE DECLINE - Diagnostics revenue fell due to loss of oncology assets, lower reimbursement rates and reduced testing volumes

Company press release: ID:nGNXjcq43

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q1 Revenue from Services
$72.2 mln
Q1 Net Income
-$54.80 mln
Q1 Basic EPS
-$0.07
Q1 Operating Income
-$51 mln
Q1 Pretax Profit
-$60.90 mln


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 5 "strong buy" or "buy", 2 "hold" and no "sell" or "strong sell"

The average consensus recommendation for the healthcare facilities & services peer group is "buy"

Wall Street's median 12-month price target for OPKO Health Inc is $3.00, about 150% above its April 27 closing price of $1.20

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

 (This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)